Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Inhaled Treprostinil

Phase 3

United Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Progressive Pulmonary FibrosisRecruiting

Progressive Pulmonary FibrosisPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Progressive Pulmonary Fibrosis

NCT05943535

Clinical

Trials by Indication[1]

Progressive Pulmonary Fibrosis1 trial

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Recruiting· United Therapeutics logo

United Therapeutics·Phase 3·NCT05943535·698 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Inhaled Treprostinil. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Inhaled Treprostinil. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — United Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: United Therapeutics

Related News